Juventas launches early-stage stem cell trial; AcelRx names former Tercica president as new CEO;

 @FierceBiotech: Florida city carves out 1-square-mile biotech hub. Article | Follow @FierceBiotech

 @JohnCFierce: Biotech Deal Activity Takes a Breather. Report. It's been too quiet on that front. I hate dull. | Follow @JohnCFierce

> Juventas has begun an early-stage trial of its experimental stem cell therapy, which is designed to repair damaged hearts. Story

> AcelRx Pharmaceuticals named Richard King as president and chief executive officer. King had been president and general manager of Tercica, which was acquired by Ipsen SA in 2008. AcelRx release

> Valeant Pharmaceuticals will offer $350 million in unsecured notes. Valeant release

> Cephalon completed its $250 million acquisition of Ception Therapeutics late Monday. Story

And Finally... An estimated 10 million American adults have all the symptoms of ADHD, and fewer than a quarter of them know. Story

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.